がん疼痛患者におけるタペンタドールの副作用と薬物動態へ影響を及ぼす因子に関する研究

1) 厚生労働省, 2018 年人口動態統計月報年計（概数）の概況,(https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai18/dl/kekka30-190626.pdf), (2020 年 12 月 17日アクセス).

2) National Cancer Center, Cancer Information Japan. cancer registry and Statistics. up-to-date cancer statistics in Japan ( https://ganjoho.jp/reg_stat/statistics/stat/summary.html) , cited 6 July, 2020.

3) Marieke E, Janneke R, Alfons K, Harry S, Maarten K, Jacob P. High Prevalence of pain in Patients with Cancer in a Large Population-Based Study in The Netherlands. J. pain, 132(3), 312-20, 2007.

4) Stefan G, Detlev Z, Christoph D, Lukas R, Klaus L. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain, 64 (1), 107-114, 1996.

5) World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, (https://www.who.int/ncds/management/palliative-care/cancer-pain- guidelines/en/), cited January, 2019.

6) Stefan G, Armin S. Clinical pharmacology of tramadol. Clin Pharmacokinet. , 43(13), 879-923, 2004.

7) 医薬食品審査管理課, タペンタドール審査結果報告書, 2014.

8) タペンタドールインタビューフォーム, ムンディファーマ, 2018.

9) Imanaka K, Tominaga Y, Etropolski M, Ohashi H, Hirose K, Matsumura T. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.Clin Drug Investig. , 34(7), 501-11, 2014.

10) Stephen ED, David U, Akiko O, Claudia L, Jüergen H. A randomized, double-blind,phase III study comparing multiple doses of tapentadol IR,oxycodone IR, and placebo for postoperative (bunionectomy) pain. CURRENT MEDICAL RESEARCH AND OPINION, 25(3), 765-776, 2009.

11) Terlinden R, Ossig J, Fliegert F, Lange C, Gohler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects, European journal of drug metabolism and pharmacokinetics, 32, 163- 169, 2007.

12) Augusto C, Geoffrey H, Stein K, Michael IB, Cinzia B, Nathan C, Ola D, Franco C, Marie F, Magdi H, Dagny FH, Gitte J, Samuel K, Pål K, Eivor AL, Marco M, Sebastiano M, Maria N, Alessandra P, Lukas R, Colette R, Per S, Patrick CS, Davide T, Giovambattista Z. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC, Lancet Oncol. , 13(2), 58-68, 2012.

13) M Fallon, R Giusti, F Aielli, P Hoskin, R Rolke, M Sharma, CI Ripamonti. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines, Annals of Oncology 29 Supplement 4, 166-191, 2018.

14) Robert AS, Judith AP, Doralina LA, Madhuri A, Justine YB, Sorin B, Marcin C, Charles C, David C, Ellin G, Heather G, Eric H, Arif HK, Mihir MK, Susan L, Sean M, M Rachel M, Natalie M, Lisle MN, Suzanne N. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology, 17(8), 977-1007, 2019.

15) Adachi S, Abe M. Clinical Guidelines for Cancer Pain Management 2014 ( Japanese Society for Palliative Medicine, Guidline Committee) , KANEHARA and Co.,LED. Tokyo, pp29-36.

16) Keith MO, David ID, Daniel W, Ryan F, John MS. Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids. PLoS One, 14(6), 2019.

17) Giorgi M, Meizler A, Mills PC. Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: Development and validation of a new methodology. J. Pharm. Biomed. Anal. , 67-68, 148-153, 2012.

18) Hillewaert V, Pusecker K, Sips L, Verhaeghe T, Vries R, Langhans M, Terlinden R, Timmerman P. Determination of tapentadol and tapentadol-O-glucuronide in human serum samples by UPLC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. , 981-982, 40-47, 2015.

19) Bourland JA, Collins AA, Chester SA, Ramachandran S, Backer RC. Determination of tapentadol (Nucynta○R ) and N-desmethyltapentadol in authentic urine specimens by ultra-performance liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. , 34, 450-457, 2010.

20) Xu XS, Smit JW, Lin R, Stuyckens K, Terlinden R, Nandy P. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet. , 49(10) , 671-682, 2010.

21) Huntjens DR, Liefaad LC, Nandy P, Drenth HJ, Vermeulen A. Population Pharmacokinetic Modeling of Tapentadol Extended Release(ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain. Clin Drug Investig. , 36(3), 213-223, 2016.

22) Zhang L, Yan X, Nobe S, Zannikos P, Etropolski M, Nandy P. Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach. Clin Drug Investig. , 37(3), 273-283, 2017.

23) Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. , 1, 1-85, 1964.

24) Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. , 60(8), 646-649, 1973.

25) Johnson PJ, Berhane S, Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O’Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence- based approach-the ALBI grade. J Clin Oncol. , 33(6), 550-558, 2015.

26) Y Kanda. Investigation of the freely available easy-to-use software EZR for medical statistics, Bone Marrow Transplantation, 48, 452-458, 2013.

27) H.Arai, Definition of older people: Time to reconsider the definition? , Nihon Ronen Igakkai Zasshi, 56(1), 1-5, 2019.